Previous 10 | Next 10 |
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. Avat Brings Over 25 Years of Business and Commercia...
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Mar...
Capricor Therapeutics, Inc. (CAPR) Q1 2022 Earnings Conference Call May 10, 2022, 16:30 ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marban - Co-Founder, President, CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co. P...
Capricor Therapeutics press release (NASDAQ:CAPR): Q1 GAAP EPS of -$0.32. The company believes that based on the current operating plan and financial resources, the company expects that its available cash and cash equivalents of approximately $58.3M will be sufficient to cover anticipated exp...
-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- -Upfront Payment of $30 Million Received in 1 st Quarter Strengthens Cash Position and Extends Cash Runway- ...
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results...
Shares of Capricor Therapeutics Inc. (NASDAQ:CAPR) traded today at $12.31, eclipsing its 52-week high. Approximately 144 million shares have changed hands today, as compared to an average 30-day volume of 272,000 shares. Capricor Therapeutics Inc. (NASDAQ:CAPR) is currently priced 0.4% a...
SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Ma...
Gainers: DatChat (DATS) +82%. Hycroft Mining Holding Corporation (HYMC) +66%. Plantronics (POLY) +50%. Kaixin Auto (KXIN) +31%. AMC Entertainment Holdings (AMC) +25%. TC Biopharm (TCBP) +23%. Creative Medical Technology (CELZ) +21%. Immunome (IMNM) +21%. Chi...
Gainers: ORIC Pharmaceuticals (ORIC) +19%. Aptorum (APM) +16%. STAAR Surgical (STAA) +16%. Creative Medical Technology (CELZ) +13%. Tempest Therapeutics (TPST) +11%. Losers: NeuroOne Medical Technologies (NMTC) -48%. Clever Leaves (CLVR) -26%. Capricor ...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...